Want to see INBS full AI Analyst Report?
Top Page
Intelligent Bio Solutions
(NASDAQ:INBS)
Select Model
Select Model
Rating:49Neutral
Price Target:
$2.50
▲(5.93% Upside)
Action:Reiterated
Date:08/20/26
The score is held down primarily by weak financial performance (large losses, declining gross margin, and heavy cash burn), which outweighs improving short-term technical momentum. Positive corporate milestones around the FDA 510(k) program provide an offsetting catalyst, but valuation remains constrained by the company’s loss-making profile and lack of dividend support.
Positive Factors
Revenue growth
Revenue growth indicates improving commercial traction for the fingerprint drug-screening platform. Sustained adoption could expand the installed reader base and recurring cartridge demand, strengthening operating leverage as the business scales.
Negative Factors
Persistent cash burn
Deeply negative operating and free cash flow show that the business is not self-funding. Continued investment in regulatory work and commercialization may require additional financing, limiting financial flexibility until recurring revenue scales.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue growth
Revenue growth indicates improving commercial traction for the fingerprint drug-screening platform. Sustained adoption could expand the installed reader base and recurring cartridge demand, strengthening operating leverage as the business scales.
Read all positive factors
Intelligent Bio Solutions (INBS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$7.57M
Dividend YieldN/A
Average Volume (3M)67.31K
Price to Earnings (P/E)―
Beta (1Y)1.44
Revenue Growth38.09%
EPS Growth54.22%
CountryUS
Employees54
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-9.46
Shares Outstanding3,027,470
10 Day Avg. Volume140,200
30 Day Avg. Volume67,309
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.61
Price to Sales (P/S)0.80
P/FCF Ratio-0.28
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-5.18
Revenue Forecast (FY)$6.13M
Intelligent Bio Solutions Business Overview & Revenue Model
Company Description
Intelligent Bio Solutions Inc. operates as a life sciences firm focused on developing non-invasive, real-time monitoring and diagnostic solutions for both patients and their primary healthcare providers. A notable product in its portfolio is the S...
How the Company Makes Money
INBS primarily generates revenue by selling and/or leasing its fingerprint drug screening hardware (portable reader devices) and, more importantly, by selling recurring consumables (single-use test cartridges) used with the system. Additional reve...
Intelligent Bio Solutions Financial Statement Overview
Summary
Income Statement
23
Negative
Balance Sheet
48
Neutral
Cash Flow
18
Very Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 4.22M | 3.05M | 3.11M | 1.26M | 0.00 |
| Gross Profit | 2.05M | 1.25M | 1.43M | 326.67K | 0.00 |
| EBITDA | -11.29M | -9.45M | -9.05M | -9.47M | -8.33M |
| Net Income | -12.43M | -10.57M | -10.16M | -10.63M | -8.31M |
Balance Sheet | |||||
| Total Assets | 11.94M | 8.25M | 13.78M | 10.35M | 12.35M |
| Cash, Cash Equivalents and Short-Term Investments | 3.99M | 1.02M | 6.30M | 1.54M | 8.28M |
| Total Debt | 1.82M | 281.81K | 1.15M | 1.92M | 0.00 |
| Total Liabilities | 6.65M | 5.44M | 5.60M | 6.67M | 5.81M |
| Stockholders Equity | 5.51M | 3.00M | 8.33M | 3.80M | 6.62M |
Cash Flow | |||||
| Free Cash Flow | -12.05M | -9.91M | -9.79M | -7.88M | -3.74M |
| Operating Cash Flow | -11.93M | -9.68M | -9.57M | -7.38M | -3.36M |
| Investing Cash Flow | -85.57K | -231.84K | -221.43K | -694.14K | -880.22K |
| Financing Cash Flow | 14.98M | 4.60M | 14.56M | 1.44M | 0.00 |
Intelligent Bio Solutions Technical Analysis
Negative
2.36
Price Trends
2.20
Positive
2.45
Negative
4.61
Negative
Market Momentum
0.16
Negative
49.90
Neutral
25.40
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INBS, the sentiment is Negative. The current price of 2.36 is above the 20-day moving average (MA) of 2.30, above the 50-day MA of 2.20, and below the 200-day MA of 4.61, indicating a neutral trend. The MACD of 0.16 indicates Negative momentum. The RSI at 49.90 is Neutral, neither overbought nor oversold. The STOCH value of 25.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for INBS.
Intelligent Bio Solutions Risk Analysis
Intelligent Bio Solutions disclosed 58 risk factors in its most recent earnings report. Intelligent Bio Solutions reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Intelligent Bio Solutions Peers Comparison
UnderperformOutperform
Sector (51)
INBS
Intelligent Bio Solutions
2.36
-13.54
-85.16%
ISPC
iSpecimen
1.60
-28.01
-94.60%
BGLC
BioNexus Gene Lab Corp
1.53
-4.06
-72.72%
BIAF
bioAffinity Technologies, Inc.
5.19
-106.41
-95.35%
Intelligent Bio Solutions Corporate Events
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Intelligent Bio Solutions Advances FDA Fingerprinting Drug Study
Positive
Aug 11, 2026
On August 11, 2026, Intelligent Bio Solutions announced it had completed a multi-site Method Comparison Study for its Intelligent Fingerprinting Drug Screening System, the final clinical study supporting its FDA 510(k) program for codeine detectio...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Intelligent Bio Solutions Advances Fingerprint Drug Screening Program
Positive
Aug 5, 2026
On August 5, 2026, Intelligent Bio Solutions announced it had completed a Usability Study for its Intelligent Fingerprinting Drug Screening System, a key component of its FDA 510(k) submission for U.S. clearance to detect the opiate codeine.Conduc...
Business Operations and StrategyPrivate Placements and Financing
Intelligent Bio Solutions Expands Share Count Through Equity Transactions
Neutral
Aug 3, 2026
Intelligent Bio Solutions Inc. reported that, following a series of equity-related transactions, its total outstanding common shares reached 3,018,188 as of the close of business on July 31, 2026. The change reflects sales under an at-the-market o...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Intelligent Bio Solutions Advances FDA Path with Interference Study
Positive
Aug 3, 2026
On August 3, 2026, Intelligent Bio Solutions announced it had completed an Interference Study for its Intelligent Fingerprinting Drug Screening System, a key component of its FDA 510(k) submission for codeine detection in the U.S. market. Conducte...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Intelligent Bio Solutions Advances FDA 510(k) Cybersecurity Readiness
Positive
Jul 23, 2026
On July 23, 2026, Intelligent Bio Solutions announced it had resolved all cybersecurity and software-related review items tied to independent penetration testing for its planned FDA 510(k) submission, completing remediation of all medium-risk vuln...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Intelligent Bio Solutions Advances Fingerprint Drug Screening Precision
Positive
Jul 21, 2026
On July 21, 2026, Intelligent Bio Solutions announced it had completed precision testing for its Intelligent Fingerprinting Drug Screening System aimed at detecting the opiate codeine, a key component of its FDA 510(k) submission for U.S. market c...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Intelligent Bio Solutions Advances Codeine Drug Test Studies
Positive
Jun 16, 2026
On June 16, 2026, Intelligent Bio Solutions Inc. announced it had initiated an Interference Study to support an FDA 510(k) submission seeking U.S. market clearance for its Intelligent Fingerprinting Drug Screening System to detect the opiate codei...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Intelligent Bio Solutions Launches FDA Study for Codeine Test
Positive
Jun 2, 2026
On June 2, 2026, Intelligent Bio Solutions Inc. announced it had begun a multi-site Method Comparison Study to support an FDA 510(k) submission seeking U.S. clearance of its Intelligent Fingerprinting Drug Screening System for the opiate codeine. ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.